Comparison of S‐1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single‐center retrospective study

BACKGROUND: Capecitabine plus oxaliplatin (XELOX) as adjuvant therapy for gastric cancer (GC) reduces cancer recurrence and improves survival. S‐1 plus oxaliplatin (SOX) is well‐tolerated and effective against advanced GC, and also be used widely in adjuvant treatment. However, data comparing SOX an...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Zhichao, Sun, Yongkun, Zhang, Wen, Cui, Chengxu, Yang, Lin, Zhou, Aiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318315/
https://www.ncbi.nlm.nih.gov/pubmed/32077628
http://dx.doi.org/10.1111/ajco.13321

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318315/
https://www.ncbi.nlm.nih.gov/pubmed/32077628
http://dx.doi.org/10.1111/ajco.13321

Ejemplares similares